Citations (50)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Anna Kreutzman, Bhagwan Yadav, Tim H. Brummendorf, Bjorn Tore Gjertsen, Moon Hee Lee, Jeroen Janssen, Tiina Kasanen, Perttu Koskenvesa, Kourosh Lotfi, Berit Markevärn, Ulla Olsson-Strömberg, Jesper Stentoft, Leif Stenke, Stina Söderlund, Lene Udby, Johan Richter, Henrik Hjorth-Hansen & Satu Mustjoki. (2019) Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line. OncoImmunology 8:9.
Read now
Read now
Faruk Obut, Nicole Randall, Jo-Anne H. Young, Peter Valent & Celalettin Ustun. (2015) Dasatinib-induced immunosuppression and recurrent respiratory tract infections. Leukemia & Lymphoma 56:8, pages 2484-2485.
Read now
Read now
Articles from other publishers (48)
Sara Rodríguez-Mora, Magdalena Corona, Miriam Solera Sainero, Elena Mateos, Montserrat Torres, Clara Sánchez-Menéndez, Guiomar Casado-Fernández, Javier García-Pérez, Mayte Pérez-Olmeda, María Aranzazu Murciano-Antón, Javier López-Jiménez, Mayte Coiras & Valentín García-Gutiérrez. (2023) Regular Humoral and Cellular Immune Responses in Individuals with Chronic Myeloid Leukemia Who Received a Full Vaccination Schedule against COVID-19. Cancers 15:20, pages 5066.
Crossref
Crossref
Yazad D. Irani, Amy Hughes, Chung H. Kok, Jade Clarson, David T. Yeung, David M. Ross, Susan Branford, Timothy P. Hughes & Agnes S. M. Yong. (2023) Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon‐alpha. British Journal of Haematology.
Crossref
Crossref
Inge G.P. Geelen, Stein-Erik Gullaksen, Mette M. Ilander, Ulla Olssen-Strömberg, Satu Mustjoki, Johan Richter, Nicole M.A. Blijlevens, Willem M. Smit, Bjorn T. Gjertsen, Tobias Gedde-Dahl, Berit Markevärn, Malika M.A. Koppes, Peter E. Westerweel, Henrik Hjorth-Hansen & Jeroen J.W.M. Janssen. (2023) Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects. Annals of Hematology 102:6, pages 1395-1408.
Crossref
Crossref
Andrea Rodríguez-Agustín, Víctor Casanova, Judith Grau-Expósito, Sonsoles Sánchez-Palomino, José Alcamí & Núria Climent. (2023) Immunomodulatory Activity of the Tyrosine Kinase Inhibitor Dasatinib to Elicit NK Cytotoxicity against Cancer, HIV Infection and Aging. Pharmaceutics 15:3, pages 917.
Crossref
Crossref
Jack Fisher, Amber Doyle, Lara Graham, Salim Khakoo & Matthew Blunt. (2022) Disruption of the NKG2A:HLA-E Immune Checkpoint Axis to Enhance NK Cell Activation against Cancer. Vaccines 10:12, pages 1993.
Crossref
Crossref
Megan Perkins, Beatrice M. Girard, Susan E. Campbell, Grant W. Hennig & Margaret A. Vizzard. (2022) Imatinib Mesylate Reduces Neurotrophic Factors and pERK and pAKT Expression in Urinary Bladder of Female Mice With Cyclophosphamide-Induced Cystitis. Frontiers in Systems Neuroscience 16.
Crossref
Crossref
Gülden Sincan, Yasin Kalpakçı, Engin Kelkitli, Fuat Erdem, Esra Altıntaş Kuşkapan, Mete Erdemir & Aysu Timuroğlu. (2022) SARS-CoV-2 Infection in Patients with Chronic Myeloid Leukemia: A Multicenter Retrospective Study. Bakirkoy Tip Dergisi / Medical Journal of Bakirkoy 18:1, pages 65-69.
Crossref
Crossref
Kim Vettenranta, Veronika Dobsinska, Gabriella Kertész, Peter Svec, Jochen Buechner & Kirk R. Schultz. (2022) What Is the Role of HSCT in Philadelphia-Chromosome–Positive and Philadelphia-Chromosome–Like ALL in the Tyrosine Kinase Inhibitor Era?. Frontiers in Pediatrics 9.
Crossref
Crossref
Stavroula Masouridi-Levrat, Eduardo Olavarria, Simona Iacobelli, Mahmoud Aljurf, Elena Morozova, Riitta Niittyvuopio, Henrik Sengeloev, Peter Reményi, Grzegorz Helbig, Paul Browne, Arnold Ganser, Arnon Nagler, John A. Snowden, Marie Robin, Jakob Passweg, Gwendolyn Van Gorkom, Hélène Labussière Wallet, Jennifer Hoek, Henric-Jan Blok, Theo De Witte, Nicolaus Kroeger, Patrick Hayden, Yves Chalandon & Ibrahim Yakoub Agha. (2021) Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT. Bone Marrow Transplantation 57:1, pages 23-30.
Crossref
Crossref
Cybele Lara R. Abad & Raymund R. Razonable. 2022. Infectious Complications in Biologic and Targeted Therapies. Infectious Complications in Biologic and Targeted Therapies
273
292
.
Erin Naismith, Janine Steichen, Sieghart Sopper & Dominik Wolf. (2021) NK Cells in Myeloproliferative Neoplasms (MPN). Cancers 13:17, pages 4400.
Crossref
Crossref
Julian Swatler, Laura Turos-Korgul, Ewa Kozlowska & Katarzyna Piwocka. (2021) Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias. Cancers 13:6, pages 1203.
Crossref
Crossref
Elisa C. Toffoli, Abdolkarim Sheikhi, Yannick D. Höppner, Pita de Kok, Mahsa Yazdanpanah-Samani, Jan Spanholtz, Henk M. W. Verheul, Hans J. van der Vliet & Tanja D. de Gruijl. (2021) Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on Immune Function and Therapeutic Response. Cancers 13:4, pages 711.
Crossref
Crossref
Chaja F. Jacobs, Eric Eldering & Arnon P. Kater. (2021) Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19. Blood Advances 5:3, pages 913-925.
Crossref
Crossref
Lorena Vigón, Alejandro Luna, Miguel Galán, Sara Rodríguez-Mora, Daniel Fuertes, Elena Mateos, Miguel Piris-Villaespesa, Guiomar Bautista, Esther San José, José Rivera-Torres, Juan Luis Steegmann, Fernando de Ory, Mayte Pérez-Olmeda, José Alcamí, Vicente Planelles, María Rosa López-Huertas, Valentín García-Gutiérrez & Mayte Coiras. (2020) Identification of Immunological Parameters as Predictive Biomarkers of Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission. Journal of Clinical Medicine 10:1, pages 42.
Crossref
Crossref
Ulf Schmitz, Jaynish S. Shah, Bijay P. Dhungel, Geoffray Monteuuis, Phuc-Loi Luu, Veronika Petrova, Cynthia Metierre, Shalima S. Nair, Charles G. Bailey, Verity A. Saunders, Ali G. Turhan, Deborah L. White, Susan Branford, Susan J. Clark, Timothy P. Hughes, Justin J.-L. Wong & John E.J. Rasko. (2020) Widespread Aberrant Alternative Splicing despite Molecular Remission in Chronic Myeloid Leukaemia Patients. Cancers 12:12, pages 3738.
Crossref
Crossref
Lorena Vigón, Sara Rodríguez-Mora, Alejandro Luna, Virginia Sandonís, Elena Mateos, Guiomar Bautista, Juan Luis Steegmann, Nuria Climent, Montserrat Plana, Pilar Pérez-Romero, Fernando de Ory, José Alcamí, Valentín García-Gutierrez, Vicente Planelles, María Rosa López-Huertas & Mayte Coiras. (2020) Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection. Biochemical Pharmacology 182, pages 114203.
Crossref
Crossref
Masao Hagihara, Jian Hua, Morihiro Inoue, Tomoyuki Uchida, Shiro Ide, Shin Ohara & Tomoiku Takaku. (2020) Nilotinib treatment induced large granular lymphocyte expansion and maintenance of longitudinal remission in a Philadelphia chromosome-positive acute lymphoblastic leukemia. International Journal of Hematology 111:5, pages 719-723.
Crossref
Crossref
María Salgado, Javier Martinez-Picado, Cristina Gálvez, Sara Rodríguez-Mora, Belén Rivaya, Víctor Urrea, Elena Mateos, José Alcamí & Mayte Coiras. (2020) Dasatinib protects humanized mice from acute HIV-1 infection. Biochemical Pharmacology 174, pages 113625.
Crossref
Crossref
Laura Damele, Selene Ottonello, Maria Cristina Mingari, Gabriella Pietra & Chiara Vitale. (2020) Targeted Therapies: Friends or Foes for Patient’s NK Cell-Mediated Tumor Immune-Surveillance?. Cancers 12:4, pages 774.
Crossref
Crossref
Yesica Bestach, María Jazmín Toloza, Cristian Ferri, Irene Larripa & Carolina Belli. (2019) The dynamic of TNF and IL6 gene expression in chronic myeloid leukemia patients reveals early responders to imatinib. Leukemia Research 86, pages 106221.
Crossref
Crossref
Núria Climent & Montserrat Plana. (2019) Immunomodulatory Activity of Tyrosine Kinase Inhibitors to Elicit Cytotoxicity Against Cancer and Viral Infection. Frontiers in Pharmacology 10.
Crossref
Crossref
Walid Warda, Fabrice Larosa, Mathieu Neto Da Rocha, Rim Trad, Eric Deconinck, Ziad Fajloun, Cyril Faure, Denis Caillot, Marius Moldovan, Severine Valmary-Degano, Sabeha Biichle, Etienne Daguindau, Francine Garnache-Ottou, Sebastien Tabruyn, Olivier Adotevi, Marina Deschamps & Christophe Ferrand. (2019) CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor–Engineered T Cells. Cancer Research 79:3, pages 663-675.
Crossref
Crossref
Ming-Chin Chang, Hung-I Cheng, Kate Hsu, Yen-Ning Hsu, Chen-Wei Kao, Yi-Fang Chang, Ken-Hong Lim & Caleb Gonshen Chen. (2019) NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia. Frontiers in Immunology 9.
Crossref
Crossref
Stephanie Wehrstedt, Jan Kubis, Andreas Zimmermann, Heiko Bruns, Daniel Mayer, Mark Grieshober & Steffen Stenger. (2018)
The tyrosine kinase inhibitor dasatinib reduces the growth of intracellular
Mycobacterium tuberculosis
despite impairing T-cell function
. European Journal of Immunology 48:11, pages 1892-1903.
Crossref
Crossref
Laura Damele, Elisa Montaldo, Lorenzo Moretta, Chiara Vitale & Maria Cristina Mingari. (2018) Effect of Tyrosin Kinase Inhibitors on NK Cell and ILC3 Development and Function. Frontiers in Immunology 9.
Crossref
Crossref
Karen Seiter, Dominick Latremouille-Viau, Annie Guerin, Briana Ndife, Karen Habucky, Derek H. Tang, Irina Pivneva, Patrick Gagnon-Sanschagrin & George J. Joseph. (2018) Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States. Advances in Therapy 35:10, pages 1671-1685.
Crossref
Crossref
Antoine Toubert, Ali Turhan, Agnès Guerci-Bresler, Nicolas Dulphy & Delphine Réa. (2018) Lymphocytes NK : un rôle majeur dans le contrôle immunologique de la leucémie myéloïde chronique. médecine/sciences 34:6-7, pages 540-546.
Crossref
Crossref
Bettina M. Knoll & K. Seiter. (2018) Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature. Infection 46:3, pages 409-418.
Crossref
Crossref
Takeshi Kondo, Tokiko Nagamura-Inoue, Arinobu Tojo, Fumitaka Nagamura, Naoyuki Uchida, Hirohisa Nakamae, Takahiro Fukuda, Takehiko Mori, Shingo Yano, Mineo Kurokawa, Hironori Ueno, Heiwa Kanamori, Hisako Hashimoto, Makoto Onizuka, Minoko Takanashi, Tatsuo Ichinohe, Yoshiko Atsuta & Kazuteru Ohashi. (2017) Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia. American Journal of Hematology 92:9, pages 902-908.
Crossref
Crossref
Amy Hughes & Agnes S. M. Yong. (2017) Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission. Frontiers in Immunology 8.
Crossref
Crossref
Can Hekim, Mette Ilander, Jun Yan, Erin Michaud, Richard Smykla, Markus Vähä-Koskela, Paula Savola, Siri Tähtinen, Leena Saikko, Akseli Hemminki, Panu E. Kovanen, Kimmo Porkka, Francis Y.F. Lee & Satu Mustjoki. (2017) Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models. Cancer Immunology Research 5:2, pages 157-169.
Crossref
Crossref
Helena ÅgerstamNils HansenSofia von PalffyCarl SandénKristian ReckzehChristine KarlssonHenrik LilljebjörnNiklas LandbergMaria AskmyrCarl HögbergMarianne RisslerKimmo PorkkaHans Wadenvik, Satu MustjokiJohan Richter, Marcus JäråsThoas Fioretos. (2016) IL1RAP antibodies block IL-1–induced expansion of candidate CML stem cells and mediate cell killing in xenograft models. Blood 128:23, pages 2683-2693.
Crossref
Crossref
Stina Söderlund, Lisa Christiansson, Inger Persson, Henrik Hjorth-Hansen, Johan Richter, Bengt Simonsson, Satu Mustjoki, Ulla Olsson-Strömberg & Angelica Loskog. (2016) Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli. Leukemia Research 50, pages 95-103.
Crossref
Crossref
Jacob Kjell & Lars Olson. (2016) Rat models of spinal cord injury: from pathology to potential therapies. Disease Models & Mechanisms 9:10, pages 1125-1137.
Crossref
Crossref
Jacob KjellAnja FinnJingxia HaoKatrin WellfeltAnna JosephsonCamilla I. SvenssonZsuzsanna Wiesenfeld-HallinUlf ErikssonMathew AbramsLars Olson. (2015) Delayed Imatinib Treatment for Acute Spinal Cord Injury: Functional Recovery and Serum Biomarkers. Journal of Neurotrauma 32:21, pages 1645-1657.
Crossref
Crossref
Hirohisa Nakamae, Hideo Koh, Takako Katayama, Mitsutaka Nishimoto, Yoshiki Hayashi, Yasuhiro Nakashima, Takahiko Nakane, Mika Nakamae, Asao Hirose & Masayuki Hino. (2015) HLA haploidentical peripheral blood stem cell transplantation using reduced dose of posttransplantation cyclophosphamide for poor-prognosis or refractory leukemia and myelodysplastic syndrome. Experimental Hematology 43:11, pages 921-929.e1.
Crossref
Crossref
Yuji Shimura, Shigeo Horiike, Yasuhiko Tsutsumi, Mayumi Hatsuse, Akira Okano, Shin-ichi Fuchida, Tsutomu Kobayashi, Yosuke Matsumoto, Junya Kuroda, Eri Kawata-Iida, Hitoji Uchiyama, Nobuhiko Uoshima, Chihiro Shimazaki, Hiroto Kaneko, Yutaka Kobayashi & Masafumi Taniwaki. (2015) The longitudinal analysis of large granular lymphocytosis in patients with Philadelphia chromosome-positive leukemia treated with dasatinib. International Journal of Hematology 102:4, pages 426-433.
Crossref
Crossref
Mark ReinwaldTobias BochWolf-Karsten HofmannDieter Buchheidt. (2016) Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors. Biomarker Insights 10s3, pages BMI.S22430.
Crossref
Crossref
Jacob Kjell & Lars Olson. (2015) Repositioning imatinib for spinal cord injury. Neural Regeneration Research 10:10, pages 1591.
Crossref
Crossref
Brian Rini. (2014) Future Approaches in Immunotherapy. Seminars in Oncology 41, pages S30-S40.
Crossref
Crossref
Mette Ilander, Can Hekim & Satu Mustjoki. (2014) Immunology and Immunotherapy of Chronic Myeloid Leukemia. Current Hematologic Malignancy Reports 9:1, pages 17-23.
Crossref
Crossref
Eva NievergallHayley S. Ramshaw, Agnes S. M. Yong, Mark Biondo, Samantha J. Busfield, Gino Vairo, Angel F. Lopez, Timothy P. HughesDeborah L. WhiteDevendra K. Hiwase. (2014) Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells. Blood 123:8, pages 1218-1228.
Crossref
Crossref
Mike Leach, Mark Drummond & Allyson Doig. 2013. Practical Flow Cytometry in Haematology Diagnosis. Practical Flow Cytometry in Haematology Diagnosis
152
172
.
Stephanie C Casey, David I Bellovin & Dean W Felsher. (2013) Noncanonical roles of the immune system in eliciting oncogene addiction. Current Opinion in Immunology 25:2, pages 246-258.
Crossref
Crossref
Nishith Singh, James Hodge, Ravi Madan & James L. Gulley. 2013. The Tumor Immunoenvironment. The Tumor Immunoenvironment
621
642
.
Aurélien Marabelle & Christophe Caux. (2012) Combined targeted and immunotherapy: the future of personalized medicine. Blood 120:23, pages 4454-4455.
Crossref
Crossref
Peter Rohon. (2012) Biological therapy and the immune system in patients with chronic myeloid leukemia. International Journal of Hematology 96:1, pages 1-9.
Crossref
Crossref